Please assess the completion status of the following clinical trial:

Trial Title: Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Newly diagnosed symptomatic multiple myeloma confirmed by the following:~  * Bone marrow plasmacytosis with at least 10% plasma cells or sheets of plasma cells or biopsy-proven plasmacytosis~ * Monoclonal protein (M protein) at least 1.0 g/dL on serum protein electrophoresis or at least 200 mg of monoclonal light chain on a 24-hour urine protein electrophoresis~* No smoldering myeloma or monoclonal gammopathy of undetermined significance~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* ECOG 0-2~Life expectancy:~* Not specified~Hematopoietic:~* Absolute neutrophil count greater than 1,000/mm\^3~* Platelet count greater than 50,000/mm\^3~* Hemoglobin greater than 7 g/dL~Hepatic:~* Bilirubin no greater than 1.5 mg/dL~* ALT and AST no greater than 2.5 times upper limit of normal~Renal:~* Creatinine less than 3 mg/dL~Cardiovascular:~* No prior or concurrent deep venous thrombosis~Other:~* Prior malignancy allowed provided the following criteria are met:~  * Received prior treatment with curative intent~ * Free of disease for the time period appropriate for cure of the specific cancer~* No grade 2 or greater peripheral neuropathy due to other medical conditions~* No active infection~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use 1 highly effective method and 1 additional method of contraception for 1 month before, during, and for 4 weeks after study for women and effective barrier contraception for men during and for 4 weeks after study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No prior biologic therapy for multiple myeloma~* No other concurrent biologic therapy for multiple myeloma~Chemotherapy:~* No prior chemotherapy for multiple myeloma~* No other concurrent chemotherapy for multiple myeloma~Endocrine therapy:~* More than 6 months since prior systemic dexamethasone or glucocorticoids~* No concurrent corticosteroids~Radiotherapy:~* At least 4 weeks since prior palliative, localized radiotherapy~* Concurrent palliative, localized radiotherapy allowed at the physician's discretion~Surgery:~* Not specified~Other:~* No prior systemic therapy for multiple myeloma, except bisphosphonates~* No concurrent anticoagulant therapy for deep vein thrombosis~* No concurrent barbiturates or alcohol (thalidomide arm)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).